Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

3D in vitro Human Stem Cell-derived Cardiovascular Tissue Model and Microfluidic Platform for Targeted Preclinical Drug Screening

Award Number: SC2GM144164
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2027

Group Awards By:

View Award Description

3D in vitro Human Stem Cell-derived Cardiovascular Tissue Model and Microfluidic Platform for Targeted Preclinical Drug Screening - PROJECT ABSTRACT: Cardiovascular Diseases (CVDs) are difficult to study and treat with pharmacological interventions due to the need for personalized medicine regimens, limited availability of human myocardium samples, and the difficulty associated with culturing primary cardiomyocytes in vitro for preclinical drug testing. In vivo animal studies are currently used to screen novel CVD therapeutics but are inefficient due to the associated high cost and advanced technical skill level. Incorporating human induced pluripotent stem cell (hiPSC) derived cardiovascular cells into relevant microfluidic devices provides a controlled, reproducible, and patient-specific (targeted) platform to study in vitro the complex process of CVD progression along with the cellular response to biochemical and biophysical changes in their microenvironments. Current in vitro cardiovascular tissue models incorporate cells from different sources and have not yet demonstrated a functional integration of cardiomyocytes with capillary-like networks composed of endothelial cells. Furthermore, microfluidic devices used with these models predominantly rely on external pumps to move fluid through the system. My long-term goals are to develop a patient-specific cardiovascular tissue model and autonomous-flow microfluidic culture platform to: 1) assess the effects of pharmaceutical drug exposure on human myocardium in vitro and 2) conduct fundamental studies of real-time cardiomyocyte-endothelial cell-extracellular matrix interaction for cardiomyopathy, atrial fibrillation, and atherosclerosis. The central hypothesis is that combining hiPSC derived 3D cardiovascular tissue with an autonomous-flow microfluidic device will create a patient-specific, physiologically relevant model that facilitates in vitro study of functional human myocardium. The primary impact of this work is development of a targeted, single source cardiovascular tissue model that will contribute to more effective drug discovery by reflecting human response to therapeutics and help reduce the use of costly animal models. This work also contributes to expanding the genetic diversity in preclinical drug testing studies so results are more representative of the general population.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2024	THE UNIVERSITY OF TEXAS AT EL PASO	500 W UNIVERSITY AVE	EL PASO	TX	79968	EL PASO	USA	Biomedical Research and Research Training	000	3	8/26/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	THE UNIVERSITY OF TEXAS AT EL PASO	500 W UNIVERSITY AVE	EL PASO	TX	79968	EL PASO	USA	Biomedical Research and Research Training	000	3	8/11/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $153,500 )
2024	2024	THE UNIVERSITY OF TEXAS AT EL PASO	500 W UNIVERSITY AVE	EL PASO	TX	79968	EL PASO	USA	Biomedical Research and Research Training	000	3	8/14/2024	NON-COMPETING CONTINUATION	$153,500
														Subtotal = $153,500

Issue Date FY: 2023 ( Subtotal = $153,500 )
2023	2023	UNIVERSITY OF TEXAS AT EL PASO	500 W UNIVERSITY AVE	EL PASO	TX	79968	EL PASO	USA	Biomedical Research and Research Training	000	2	8/15/2023	NON-COMPETING CONTINUATION	$153,500
														Subtotal = $153,500

Issue Date FY: 2022 ( Subtotal = $148,150 )
2022	2022	UNIVERSITY OF TEXAS AT EL PASO	500 W UNIVERSITY AVE	EL PASO	TX	79968	EL PASO	USA	Biomedical Research and Research Training	000	1	8/30/2022	NEW	$148,150
														Subtotal = $148,150

Grand Total All Awards = $455,150

Top

All Categories

About

Search

Reports

Data Submission

Award Information

3D in vitro Human Stem Cell-derived Cardiovascular Tissue Model and Microfluidic Platform for Targeted Preclinical Drug Screening

Award Number: SC2GM144164

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer